Our aim was to compare the candidacy and insurance coverage for treating newly discovered CHC patients. METHODS: The National Health and Nutrition Examination Survey (NHANES) conducted between 2005-2012 was used. The study span was split into two cycles: 2005-2008 and 2009-2012. Using medical history questionnaire completed by the NHANES participants, IFN ineligibility was defined as having history of major chronic diseases (severe depression,
cardio-pulmo-nary diseases, kidney failure) while ineligibility for IFN-free regimens only included kidney failure.. RESULTS: A total of 10,799 and 11,840 adult (18+) NHANES participants were included in the two NHANES cycles. Of these, Selleck PLX4032 1.19% and 0.94%, respectively showed detectable HCV viremia (HCV+). Of the HCV+ cohort, 133 (94.5% Cycle 1)) and 130 (100% Cycle 2) had completed insurance and medical history questionnaires. HCV+ subjects were 63.0% Caucasian and 67.3% male (similar in both cycles, p>0.05). RXDX-106 in vitro The proportion of individuals aged ≥65 increased from 1.7% in 2005-2008 to 6.8% in 2009-2012 (p=0.0144). HCV+ individuals were less likely to be insured than HCV- individuals regardless of the study year (HCV+: 63.8% vs. HCV-: 80.1%, p=0.0005). Compared to 2005-2008 (Cycle 1), the rate of insurance coverage insignificantly increased from 60.2% (Cycle
1) to 67.4% (Cycle 2) (p=0.38), predominantly due to an increase in Medicare/Med-icaid eligibility (19.0% to 25.3%, p=0.38). Treatment eligibility (based on medical contraindications) increased from 66.6% to 74.1% for interferon-based regimens (p>0.05). After applying treatment eligibility for IFN-free RBV-free regimens, 95.1% (Cycle 1) and 97.7% (Cycle 2) were eligible for treatment despite ageing of the study population and unchanged rates of all studied comorbid conditions. Finally, considering both treatment eligibility and insurance coverage increased from 35.5% with IFN-containing regimens to 66.6% with IFN-free regimens (p=0.0003). CONCLUSIONS: Given the significantly better side effect profile of the newly
developed IFN- and RBV-free regimens with minimal contraindications, an important Metalloexopeptidase barrier to HCV treatment (treatment eligibility) has been addressed. Nevertheless, a large proportion of HCV+ patients remain uninsured, under-insured or insured through publicly funded health insurance. As the Affordable Care Act and healthcare reform laws are being implemented, providing adequate coverage for HCV patients remains critical. Disclosures: Brian P. Lam – Advisory Committees or Review Panels: BMS; Speaking and Teaching: Gilead; Stock Shareholder: Gilead The following people have nothing to disclose: Zobair Younossi, Maria Ste-panova, Manirath Srishord, Spencer Frost, Huong T. Pham, Andrei Racila, Mariam Afendy, Thomas Jeffers Health-related quality of life (HRQOL) is an important determinant of daily function and prognosis in cirrhosis and hepatic encephalopathy (HE).